Additionally, WNT3 silencing inhibited CFC production of CML CD34+ cells (Fig. 5E, F) and sensitized these cell to IM treatment (Fig. 5G). The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.